SBIR/STTR Research Award
Functional Analogs of Cellular Phosphoinositides
Award amount
$99,992Program and phase
SBIR · Phase IAward year
2001Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- NUTRIMED BIOTECH
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by applicant): The cellular phosphoinositides, including
the phosphatidylinositols and their mono- and polyphosphate derivatives, are
critical in intracellular signaling and related cascades. We have developed
methods for synthesizing analogs of the cellular series, and the synthetic
products are now established as important in vitro reagents. The available
synthetic phosphoinositides are not consistently membrane-permeant.
Heptakis(acetoxymethyl) derivatives of pbosphatidylinositol-3,4,5-trisphospbate
(Ptdlns-3,4,5-P3) enter cells and display activity of Ptdlns-3,4,5-P3. However,
polykis-acetoxymethylated phosphoinositides have serious inherent drawbacks as
reagents because these suffer extensive phosphate shifts resulting in mixtures
of isomers and provide a variable indeterminate amount of the unmodified
phosphoinositide inside cells.
The overall objective of this investigation is to develop membrane-permeant
functional analogs of the phosphoinositides. During Phase I, an approach
integrating the design, synthesis and evaluation of novel fonnulations will be
tested to assess internalization of synthetic
phosphatidylinositol-4,5-bisphosphate (Ptdlns4,5-P2) analogs in cells. During
Phase II, the approach will be optimized for Ptdlns-4,5-P2 and extended to a
complete range of phosphoinositide analogs.
PROPOSED COMMERCIAL APPLICATION:
This research will provide a reliable means for introducting quantitatively controlled amounts
of exogenous phosphoinositides into intact live cells, and a complete range of novel
membrane-permeant phosphoinositide products for use as in vivo research reagents for
studies ranging from cell physiology to delivery of phosphoinositide-based therapeutics.
These products are in demand but not currently available from any commercial source,
and are suitable for transfer directly from production in a laboratory setting to the market.
Technology keywords
Not reported